Network News

21 May 2020

BNP Paribas Hong Kong - Thank You!

The HKU-Pasteur Research Pole wishes to express its heartfelt gratitude to BNP Paribas Hong Kong for its generous pledge to support the Pasteur Foundation Asia for research on SARS-CoV-2, the causative agent of the pandemic COVID-19

The HKD500,000 donation will allow PFA to fund projects at HKU-Pasteur Research Pole and the Institut Pasteur in Cambodia, where crucial work on the immune response to SARS-CoV-2 and development of diagnostic tests for COVID-19 are conducted.

This contribution is a major step towards PFA’s goal to raise HKD5,000,000 to fund current research on the SARS-CoV-2 and support laboratories of the Pasteur Network inlow and middle income countries to face the enormous challenge posed by this newly emerged zoonotic virus and address risks of spill-over of other viruses from the animal reservoirs into humans.

Our efforts will be continued in the long run to overcome the pandemic and prepare a safe and secure environment for everyone. 

Donations are crucial to achieve this goal and keep Hong Kong at the forefront of biomedical research on infectious diseases.

BNP Paribas Hong Kong and HKU-Pasteur Research Pole have been in a privileged partnership that has supported research on Dengue virus, and training of young scientists at HKU-Pasteur Virology Courses.


07 May 2020

Revealing how SARS-CoV-2 hijacks human cells points to drugs with potential to fight COVID-19 and a drug that aids its infectious growth

An international effort including researchers from University of California San Francisco (UCSF), Gladstone Institutes, Icahn School of Medicine at Mount Sinai and Institut Pasteur (Paris) unveils promising compounds for clinical testing against COVID-19. The study, led by UCSF Quantitative Biosciences Institute Director, Nevan Krogan, PhD, reveals that some drugs may fight COVID-19 while another promotes infectivity. These results were published in Nature: A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

An international team of more than 120 scientists has detailed the impact of 75 over-the-counter prescription and development-stage drug compounds on SARS-CoV-2, the virus that causes COVID-19. Several of these agents show promise in blocking SARS-CoV-2 replication in laboratory experiments. One compound investigated in the research, a common ingredient in over-the-counter cough medicines, appears to have the potential to promote the growth of the virus.
The collaborative study, published in Nature on April 30, 2020, was assembled and led by Nevan Krogan, PhD, director of the Quantitative Biosciences Institute at UC San Francisco and a senior investigator at Gladstone Institutes. As the first hints of the pandemic emerged in January, over a matter of just a few weeks, Krogan formed a rapid-response research team of dozens of scientists and clinicians -- hailing from UCSF, Gladstone, Icahn School of Medicine at Mount Sinai in New York, and Institut Pasteur in Paris -- to search for potential treatments for COVID-19.
Rather than focusing on an antiviral approach to block SARS-CoV-2, the researchers first combined biological and computational techniques to create a “blueprint” of more than 300 human proteins that the virus requires to infect human cells and to thrive and replicate in the body. They then explored the question of which drugs, both those that are currently marketed as well as those in development, might be repurposed to treat SARS-CoV-2 infection by targeting those human proteins.
The researchers emphasized that while the drugs identified in the study are promising, they have only been tested against the virus in laboratory experiments. The researchers do not advocate anyone prescribing and/or using the drugs unless human clinical trials find them to be safe and effective.

05 May 2020

Pasteur Foundation Asia - Together, We Will Overcome The SARS-CoV-2 Virus

The Pasteur Foundation Asia (PFA), charitable organization established in Hong Kong that supports crucial scientific research, teaching and public health initiatives, started a fundraising campaign to support the response against the SARS-CoV-2.

With the goal of raising HKD5,000,000, the PFA will support technology transfer and sending material in the Asia-Pacific region and where people need them most. Those funds will also help current research on the SARS-CoV-2 in Hong Kong at HKU-Pasteur and across the Institut Pasteur International Network as well as supporting teaching to prepare future generations of scientists. 

"We need to prepare ourselves for the long run and scientific knowledge is the answer." Roberto Bruzzone, Co-Director, HKU-Pasteur